AZ’s Airsupra (albuterol and budesonide ... approval means the device is now approved for use with all triple-therapy inhalers in the US market. Adherium’s chief executive, Dr Paul ...

The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic ... PT010 is based on the inhaled corticosteroid budesonide, long-acting muscarinic antagonist (LAMA ...

In the context of the state protocol in force until 2021, patients with severe or very severe COPD treated in our service ... to umeclidinium 62.5 mcg + vilanterol 25 mcg. Forty-one were on triple ...

Asthma–chronic obstructive pulmonary disease (COPD ... clinical phenotype(s), then to determine the best available therapy. The authors discuss the array of existing and emerging classes ...

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

As such, it matches the huge surface areas of the alveolar epithelium to the pulmonary blood capillaries ... way was to use combination of inhaled corticosteroid and inhaled β2 agonist. In a recently ...

Conclusions Together, our data indicate that budesonide suppresses epithelial proinflammatory responses and barrier dysfunction and that oxidative stress reduces these effects in airway epithelium ...